Clinical Trials Logo
  1. Home
  2. Flu
  3. NCT03293979
  4. Details
NCT03293979 Clinical Trial

Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis

Flu Clinical Trial

Official title:
Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03293979
Other study ID # TestAiFluA&B
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 22, 2016
Est. completion date June 30, 2018

Study information
Verified date August 2018
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It appears that the heavyness of flu pathology, the diagnosis limits and the validity of it was well studied in the last years.However, the economical impact and the organisation benefit in emergency service is not yet evaluated Our purpose is to study the impact of implementation of fast flu diagnosis by molecular biology available in emergency service in the economic field .

Recruitment information / eligibility
Status Completed
Enrollment 301
Est. completion date June 30, 2018
Est. primary completion date December 31, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- respiratory symptoms

- fever >38°C

- general symptoms of flu like pathology

Exclusion Criteria:

- cognitive disorders

- patient with guardianship

- patient already having a flu diagnosis in the last 7 days

- without social protection.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Test A i Flu A&B implemented in emergency service
Test A i Flu A&B implemented in emergency service

Locations
Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)
Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary time to have the result of the biological test 3 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06057727 - Behavioral Economics to Improve Flu Vaccination Using EHR Nudges N/A
Completed NCT03694808 - FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care Phase 4
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT01440205 - Licensing Flu Shot Study N/A
Terminated NCT00769002 - PET-CT Scans in Healthy Volunteers After Flu Vaccination N/A
Completed NCT03308825 - Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines Phase 4
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT01484522 - Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth N/A
Completed NCT03344029 - Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years Phase 4
Completed NCT01459952 - A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold Phase 3
Completed NCT00644540 - Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study Phase 2
Recruiting NCT06158659 - Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula N/A
Completed NCT05417997 - Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients Phase 3
Completed NCT01389518 - Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome Phase 3
Completed NCT02822105 - Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers Phase 1
Withdrawn NCT02037282 - A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects Phase 1
Completed NCT04153331 - Burden of Influenza at Emergency Department Level : BIED N/A
Not yet recruiting NCT05473325 - Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
Completed NCT01533220 - Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Phase 3
Recruiting NCT04515446 - Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza N/A